Mersana Therapeutics to Present at the Upcoming Stifel 2021 Virtual Healthcare Conference
November 10 2021 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that Anna
Protopapas, President and Chief Executive Officer, will present a
company overview at the Stifel 2021 Virtual Healthcare
Conference on Wednesday, November 17, 2021, at 3:20 p.m. ET.
A live webcast of the presentation will be available on the
Investors & Media section of Mersana’s website at
www.mersana.com. An archived replay will be available for
approximately 90 days following the event.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage
biopharmaceutical company using its differentiated and proprietary
ADC platforms to rapidly develop novel ADCs with optimal efficacy,
safety and tolerability to meaningfully improve the lives of people
fighting cancer. Mersana’s lead product candidate, upifitamab
rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is
being studied in UPLIFT, a single-arm registration strategy in
patients with platinum-resistant ovarian cancer, as well as in
UPGRADE, a Phase 1 umbrella study in combination with other ovarian
cancer therapies. XMT-1592, Mersana’s second ADC product candidate
targeting NaPi2b-expressing tumors, was created using Mersana’s
customizable and homogeneous Dolasynthen platform and is in the
dose escalation portion of a Phase 1 proof-of-concept clinical
study. The Company’s early-stage programs include XMT-1660, a
Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a
STING-agonist ADC developed using the Company’s Immunosynthen
platform and targeting a novel epitope of human epidermal growth
factor receptor 2 (HER2). In addition, multiple partners are using
Mersana’s Dolaflexin platform to advance their ADC pipelines. The
Company routinely posts information that may be useful to investors
on the “Investors and Media” section of our website at
www.mersana.com.
Contact:
Investor & Media ContactSarah
Carmody617-844-8577scarmody@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Apr 2023 to Apr 2024